× NICE uses cookies to make the site better.  Learn more
A-Z
Topics
Latest


Metastatic spinal cord compression

About

What is covered

This interactive flowchart covers detecting and managing metastatic spinal cord compression in adults with cancer that has spread to the spine. It aims to improve quality of life by promoting early detection and management, and reducing spinal cord damage and disability.

Updates

Updates to this interactive flowchart

27 February 2017 Degarelix for treating advanced hormone-dependent prostate cancer (NICE technology appraisal guidance 404) added to drug treatments for specific cancers. Restructured, and summarised recommendations replaced with full recommendations.
26 February 2014 Metastatic spinal cord compression (NICE quality standard 56) added.
23 October 2012 Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (NICE technology appraisal guidance 265) added to drug treatments for specific cancers.

Person-centred care

People have the right to be involved in discussions and make informed decisions about their care, as described in your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

Your responsibility

Guidelines

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Technology appraisals

The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take these recommendations fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this interactive flowchart is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the recommendations to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Medical technologies guidance, diagnostics guidance and interventional procedures guidance

The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take these recommendations fully into account. However, the interactive flowchart does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the recommendations, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this interactive flowchart should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Short Text

Everything NICE has said on detecting and managing metastatic spinal cord compression in adults with cancer in an interactive flowchart

What is covered

This interactive flowchart covers detecting and managing metastatic spinal cord compression in adults with cancer that has spread to the spine. It aims to improve quality of life by promoting early detection and management, and reducing spinal cord damage and disability.

Updates

Updates to this interactive flowchart

27 February 2017 Degarelix for treating advanced hormone-dependent prostate cancer (NICE technology appraisal guidance 404) added to drug treatments for specific cancers. Restructured, and summarised recommendations replaced with full recommendations.
26 February 2014 Metastatic spinal cord compression (NICE quality standard 56) added.
23 October 2012 Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (NICE technology appraisal guidance 265) added to drug treatments for specific cancers.

Sources

NICE guidance and other sources used to create this interactive flowchart.
Degarelix for treating advanced hormone-dependent prostate cancer (2016) NICE technology appraisal guidance 404
Percutaneous cementoplasty for palliative treatment of bony malignancies (2006) NICE interventional procedures guidance 179
Balloon kyphoplasty for vertebral compression fractures (2006) NICE interventional procedures guidance 166
Direct C1 lateral mass screw for cervical spine stabilisation (2005) NICE interventional procedures guidance 146
Percutaneous vertebroplasty (2003) NICE interventional procedures guidance 12
Metastatic spinal cord compression in adults (2014) NICE quality standard 56

Quality standards

Quality statements

Information about recognising the symptoms of metastatic spinal cord compression

This quality statement is taken from the metastatic spinal cord compression in adults quality standard. The quality standard defines clinical best practice in metastatic spinal cord compression care for adults and should be read in full.

Quality statement

Adults at high risk of developing metastatic spinal cord compression (MSCC), and their families or carers (as appropriate), are given information that describes the symptoms of MSCC and what to do if they develop symptoms.

Rationale

It is important that adults at high risk of developing MSCC, and their or carers (as appropriate), receive information about how to recognise the symptoms of MSCC so they can seek help to ensure prompt diagnosis and treatment. If people have information they are empowered to manage their condition, which can lead to early detection and improved outcomes. Healthcare professionals should carefully consider the timing of giving information, because adults with cancer receive a wide variety of supporting information about the disease. It is important to communicate information about MSCC clearly, and to emphasise the importance of being aware of the symptoms.

Quality measures

Structure
Evidence of local arrangements and written clinical protocols to ensure that adults at high risk of developing MSCC, and their families or carers (as appropriate), are given information that describes the symptoms of MSCC and what to do if they develop symptoms.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-1E-105y (Network Information on Early Detection of MSCC) and 11-3Y-311 (Patient Information on Early Detection of MSCC) Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011).
Process
Proportion of adults identified as at high risk of developing MSCC, or their families or carers, who receive information that describes the symptoms of MSCC and what to do if they develop symptoms.
Numerator – the number of adults in the denominator or their family member or carer who receive information when they are identified as at risk that describes the symptoms of MSCC and what to do if they develop symptoms.
Denominator – the number of adults identified as at high risk of developing MSCC.
Data source: Local data collection. NICE audit support for Metastatic spinal cord compression (NICE clinical guideline 75).

What the quality statement means for service providers, healthcare professionals and commissioners

Service providers ensure that patient information about the symptoms of MSCC is available, and that healthcare professionals are trained to understand and explain the information and to give it to adults at high risk of developing MSCC, and their families or carers (as appropriate).
Healthcare professionals in both primary and secondary care ensure that they understand and can explain the patient information about the symptoms of MSCC, and that they give this information to adults at high risk of developing MSCC, and their families or carers (as appropriate).
Commissioners ensure that they commission services that provide patient information about the symptoms of MSCC, and that they train healthcare professionals to understand and explain the information and give it to adults at high risk of developing MSCC, and their families or carers (as appropriate).

What the quality statement means for patients, service users and carers

Adults at high risk of MSCC, and their families or carers (as appropriate), are given information that describes the symptoms to look out for, and advice on what to do if they notice any symptoms of MSCC developing.

Source guidance

  • Metastatic spinal cord compression (NICE clinical guideline 75), recommendation 1.3.1.1 (key priority for implementation).

Definitions of terms used in this quality statement

Adults at high risk of MSCC
Adults with cancer who have, or who are at high risk of developing, bone metastases, and adults with cancer who present with spinal pain. [Adapted from NICE clinical guideline 75 recommendation 1.3.1.1]
Adults at high risk of developing bone metastases
This group includes, but is not limited to, adults with known cancer of the lung, breast or prostate, or myeloma. The risk can be determined by identifying the tumour site, grade and stage at presentation. [Definition developed from expert consensus]
Information that describes the symptoms of MSCC
Information may be in the form of, for example, a leaflet, a ‘red flag’ card, or audio/visual materials. It should list the early warning symptoms of MSCC, together with clear advice on what action to take if any symptoms develop.
NICE has produced information for the public about MSCC. In addition, the full clinical guideline on MSCC includes an example of a patient information leaflet. [Definition developed from the full clinical guideline 75 appendix 2 and expert consensus]
Symptoms of MSCC
The following symptoms are suggestive of MSCC:
  • progressive pain in the spine
  • severe unremitting spinal pain
  • spinal pain aggravated by straining (for example, when passing stools, when coughing or sneezing, or when moving)
  • pain described as ‘band like’
  • localised spinal tenderness
  • nocturnal spinal pain preventing sleep
  • neurological symptoms: radicular pain, any limb weakness, difficulty in walking, sensory loss, or bladder or bowel dysfunction.
[Definition developed from NICE clinical guideline 75 recommendations 1.3.2.1 and 1.3.2.2 and expert consensus]

Equality and diversity considerations

All information given about the symptoms of MSCC and what to do if symptoms develop should be accessible to people with additional needs, such as physical, sensory or learning disabilities, and to people who do not speak or read English. Adults at high risk of developing MSCC should have access to an interpreter or advocate if needed.

Imaging and treatment plans for adults with suspected spinal metastases

This quality statement is taken from the metastatic spinal cord compression in adults quality standard. The quality standard defines clinical best practice in metastatic spinal cord compression care for adults and should be read in full.

Quality statement

Adults with spinal pain suggestive of spinal metastases, but with no neurological symptoms or signs, have an MRI of the whole spine and any necessary treatment plan agreed within 1 week of the suspected diagnosis.

Rationale

Adults with spinal pain suggestive of spinal metastases need timely access to imaging that will accurately identify spinal metastases. Whole-spine MRI is central to the diagnosis, staging and planning of treatment. If spinal metastases are suspected, it is essential that investigation, planning and treatment take place before any loss of neurological function occurs. To reduce the risk of avoidable disability for adults with suspected spinal metastases, it is important that an MRI is performed and that treatment is planned by senior clinical advisers, within 1 week of the suspected diagnosis.

Quality measures

Structure
Evidence of local arrangements and written protocols to ensure that adults with spinal pain suggestive of spinal metastases, but with no neurological symptoms or signs, have an MRI of the whole spine and any necessary treatment plan agreed within 1 week of the suspected diagnosis.
Data source: Local data collection.
Process
a) Proportion of adults with spinal pain suggestive of spinal metastases, but with no neurological symptoms or signs, who receive an MRI of the whole spine within 1 week of the suspected diagnosis.
Numerator – the number of adults in the denominator who receive an MRI of the whole spine within 1 week of presenting with spinal pain suggestive of spinal metastases, but with no neurological symptoms or signs.
Denominator – the number of adults who present with spinal pain suggestive of spinal metastases, but with no neurological symptoms or signs.
b) Proportion of adults with spinal metastases confirmed by MRI of the whole spine, but with no neurological symptoms or signs, who have a treatment plan agreed within 1 week of the suspected diagnosis.
Numerator – the number of adults in the denominator who have a treatment plan agreed within 1 week of presenting with spinal pain suggestive of spinal metastases, but with no neurological symptoms or signs.
Denominator – the number of adults with spinal metastases confirmed by MRI of the whole spine, but with no neurological symptoms or signs.
Data source: Local data collection. British Spine Registry Spinal tumour data (2013).
Outcome
a) Proportion of adults with spinal metastases who are able to walk within 3 months of treatment.
b) Proportion of adults with spinal metastases who are able to walk within 2 years of treatment.
c) Rates of mortality within 30 days of treatment.
Data source: Local data collection. British Spine Registry Spinal tumour data (2013).

What the quality statement means for service providers, healthcare professionals and commissioners

Service providers ensure that adequate capacity is available for whole-spine MRI scanning and treatment planning to be undertaken within 1 week for adults with suspected spinal metastases who present with spinal pain but with no neurological symptoms or signs.
Healthcare professionals ensure that they perform an MRI of the whole spine for adults with suspected spinal metastases who present with spinal pain but with no neurological symptoms or signs, and agree any necessary treatment plan within 1 week of the suspected diagnosis.
Commissioners ensure that they commission services that can provide MRI scanning and treatment planning by senior clinical advisers within 1 week of the suspected diagnosis of spinal metastases for adults who have spinal pain but no neurological symptoms or signs.

What the quality statement means for patients, service users and carers

Adults with suspected spinal metastases (who have spinal pain only) have an MRI of their whole spine and, if necessary, have a plan for their treatment organised within 1 week of the suspected diagnosis.

Source guidance

  • Metastatic spinal cord compression (NICE clinical guideline 75), recommendation 1.4.3.3 (key priority for implementation).

Definitions of terms used in this quality statement

Symptoms of spinal metastases
The following symptoms are suggestive of spinal metastases:
  • progressive pain in the spine
  • severe unremitting spinal pain
  • localised spinal tenderness
  • nocturnal spinal pain preventing sleep.
[Definition developed from NICE clinical guideline 75 recommendation 1.3.2.1 and expert consensus]
Senior clinical advisers
Includes clinical oncologists, spinal surgeons and radiologists with experience and expertise in treating adults with spinal metastases. [Adapted from NICE clinical guideline 75 recommendation 1.1.2.4]
Treatment plan
A treatment plan for adults with spinal metastases should be agreed by senior clinical advisers, and the names of those involved in the discussion should be included in the documentation. Treatment planning should take account of:
  • spinal stability, which should be assessed both clinically and radiologically
  • the degree of neurological disability
  • the general health of the patient
  • the prognosis, which should be estimated using a validated scoring system
  • the primary site of tumour
  • the presence of other spinal and extraspinal metastases
  • the likely response of the tumour to radiotherapy or other adjuvant therapy
  • the patient’s care and treatment preferences.
[The full clinical guideline 75, section 6.1 and expert consensus]

Imaging and treatment plans for adults with suspected metastatic spinal cord compression

This quality statement is taken from the metastatic spinal cord compression in adults quality standard. The quality standard defines clinical best practice in metastatic spinal cord compression care for adults and should be read in full.

Quality statement

Adults with suspected metastatic spinal cord compression (MSCC) who present with neurological symptoms or signs have an MRI of the whole spine and any necessary treatment plan agreed within 24 hours of the suspected diagnosis.

Rationale

Adults with suspected MSCC who present with neurological symptoms or signs need rapid access to imaging that will accurately identify spinal cord compression. Whole spine MRI is central to the diagnosis, staging and planning of treatment. Neurological deficit at initial presentation is an important predictor of long-term functional outcome. To reduce the risk of avoidable disability for adults with suspected MSCC, it is important that both an MRI is performed and treatment is planned by senior clinical advisers, within 24 hours of the suspected diagnosis.

Quality measures

Structure
Evidence of local arrangements and written protocols to ensure that adults with suspected MSCC, who present with neurological symptoms or signs, have an MRI of the whole spine and any necessary treatment plan agreed within 24 hours of the suspected diagnosis.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-1E-110y (The MSCC Case Discussion Policy) and 11-1E-111y (The Audit of Timeliness of the Investigation of MSCC) Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011).
Process
a) Proportion of adults with suspected MSCC who present with neurological symptoms or signs who receive an MRI of the whole spine within 24 hours of the suspected diagnosis.
Numerator – the number of adults in the denominator who receive an MRI of the whole spine within 24 hours of presenting with suspected MSCC and neurological symptoms or signs.
Denominator – the number of adults with suspected MSCC who present with neurological symptoms or signs.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-1E-111y (The Audit of Timeliness of the Investigation of MSCC) Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011). British Spine Registry Spinal tumour data (2013).
b) Proportion of adults with MSCC confirmed by MRI of the whole spine, who presented with neurological symptoms or signs, who have a treatment plan agreed within 24 hours of the suspected diagnosis.
Numerator – the number of adults in the denominator who have a treatment plan agreed within 24 hours of presenting with suspected MSCC and neurological symptoms or signs.
Denominator – the number of adults with MSCC confirmed by MRI of the whole spine who presented with neurological symptoms or signs, who have a diagnosis of MSCC confirmed after an MRI of the whole spine.
Data source: Local data collection. NICE audit support for Metastatic spinal cord compression (NICE clinical guideline 75). British Spine Registry Spinal tumour data (2013).
Outcome
a) Proportion of adults with MSCC who are able to walk within 3 months of treatment.
b) Proportion of adults with MSCC who are able to walk within 2 years of treatment.
c) Rates of mortality within 30 days of treatment.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-1E-113y Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011). British Spine Registry Spinal tumour data (2013).

What the quality statement means for service providers, healthcare professionals and commissioners

Service providers ensure that adequate capacity is available for whole-spine MRI scanning and treatment planning to be undertaken within 24 hours for adults with suspected MSCC who present with neurological symptoms or signs.
Healthcare professionals ensure that they perform an MRI of the whole spine for adults with suspected MSCC who present with neurological symptoms or signs, and that if a diagnosis of MSCC is confirmed they agree a treatment plan within 24 hours of the suspected diagnosis.
Commissioners ensure that they commission services that can provide MRI scanning and treatment planning by senior clinical advisers within 24 hours of the suspected diagnosis, for adults with suspected MSCC who present with neurological symptoms or signs.

What the quality statement means for patients, service users and carers

Adults with suspected MSCC have an MRI of their whole spine and, if a diagnosis of MSCC is confirmed by the MRI, a plan for their treatment organised within 24 hours of the suspected diagnosis.

Source guidance

  • Metastatic spinal cord compression (NICE clinical guideline 75), recommendation 1.4.3.3 (key priority for implementation).

Definitions of terms used in this quality statement

Symptoms and signs of MSCC
The following symptoms and signs are suggestive of MSCC:
  • progressive pain in the spine
  • severe unremitting spinal pain
  • spinal pain aggravated by straining (for example, at stool, when coughing or sneezing, or when moving)
  • pain described as ‘band like’
  • localised spinal tenderness
  • nocturnal spinal pain preventing sleep
  • neurological symptoms: radicular pain, any limb weakness, difficulty in walking, sensory loss, or bladder or bowel dysfunction
  • neurological signs of spinal cord or cauda equina compression.
[Definition developed from NICE clinical guideline 75 recommendations 1.3.2.1 and 1.3.2.2 and expert consensus]
Senior clinical advisers
Includes clinical oncologists, spinal surgeons and radiologists with experience and expertise in treating adults with MSCC. [NICE clinical guideline 75 recommendation 1.1.2.4]
Treatment plan
A treatment plan for adults with MSCC should be agreed by senior clinical advisers, and the names of those involved in the discussion should be included in the documentation. Treatment planning should take account of:
  • spinal stability, which should be assessed both clinically and radiologically
  • the degree of neurological disability
  • the general health of the patient
  • the prognosis, which should be estimated using a validated scoring system
  • the primary site of tumour
  • the presence of other spinal and extraspinal metastases
  • the likely response of the tumour to radiotherapy or other adjuvant therapy
  • the patient’s care and treatment preferences.
[The full clinical guideline 75, section 6.1 and expert consensus]

Coordinating investigations for adults with suspected metastatic spinal cord compression

This quality statement is taken from the metastatic spinal cord compression in adults quality standard. The quality standard defines clinical best practice in metastatic spinal cord compression care for adults and should be read in full.

Quality statement

Adults with suspected metastatic spinal cord compression (MSCC) who present with neurological symptoms or signs have their diagnostic investigations coordinated by an MSCC coordinator.

Rationale

Some adults with cancer who have a high risk of developing bone metastases are at high risk of developing MSCC. When people present with suspected MSCC, it is important that diagnostic investigations are undertaken promptly. The principal role of the MSCC coordinator for adults with suspected MSCC is to liaise with healthcare professionals and ensure that investigations are organised and undertaken without delay. For those with neurological symptoms or signs it is particularly important that an MSCC coordinator is available at all times to ensure that initial management for adults with MSCC is both comprehensive and timely.

Quality measures

Structure
a) Evidence of local arrangements for identifying individuals responsible for performing the role of MSCC coordinator.
b) Evidence of local arrangements to ensure that adults with suspected MSCC who present with neurological symptoms or signs have their diagnostic investigations coordinated by an MSCC coordinator.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-3Y-304 Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011).
Process
Proportion of adults with suspected MSCC who present with neurological symptoms or signs who have an assessment of their requirement for, and urgency of investigations, undertaken by an MSCC coordinator.
Numerator – the number of adults in the denominator who have an assessment of their requirement for, and urgency of investigations, undertaken by an MSCC co-ordinator.
Denominator – the number of adults with suspected MSCC who present with neurological symptoms or signs.
Data source: Local data collection.

What the quality statement means for service providers, healthcare professionals, and commissioners

Service providers ensure that an MSCC coordinator is available at all times to coordinate the diagnostic investigations for adults with suspected MSCC who present with neurological symptoms or signs.
Healthcare professionals ensure that adults with suspected MSCC who present with neurological symptoms or signs have their diagnostic investigations organised by the MSCC coordinator.
Commissioners ensure that they commission services that provide access to an MSCC coordinator, available at all times, to coordinate diagnostic investigations for adults with suspected MSCC who are referred from primary or secondary care.

What the quality statement means for patients, service users and carers

Adults with suspected MSCC who have neurological symptoms or signs have their tests and investigations arranged by a coordinator.

Source guidance

Definitions of terms used in this quality statement

Adults at high risk of MSCC
Adults with cancer who have, or who are at high risk of developing, bone metastases, and adults with cancer, who present with spinal pain. [Adapted from NICE clinical guideline 75 recommendation 1.3.1.1]
MSCC coordinator role
The role involves coordinating the ongoing care of adults with MSCC and the diagnostic investigations of people at risk of developing MSCC who present with relevant symptoms. An MSCC coordinator should be available 24 hours a day, 7 days a week, acting as a single point of contact for healthcare professionals to liaise with.
The MSCC coordinator’s responsibilities and the support they should receive are described in NICE clinical guideline 75 recommendations 1.1.2.3 and 1.1.2.5.
The Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011; measure 11-3Y-304) lists the criteria that the MSCC coordinator service should fulfil.
Symptoms and signs of MSCC
The following symptoms and signs are suggestive of MSCC:
  • progressive pain in the spine
  • severe unremitting spinal pain
  • spinal pain aggravated by straining (for example, at stool, when coughing or sneezing, or when moving)
  • pain described as ‘band like’
  • localised spinal tenderness
  • nocturnal spinal pain preventing sleep
  • neurological symptoms: radicular pain, any limb weakness, difficulty in walking, sensory loss, or bladder or bowel dysfunction
  • neurological signs of spinal cord or cauda equina compression.
[Definition developed from NICE clinical guideline 75 recommendations 1.3.2.1 and 1.3.2.2 and expert consensus]

Coordinating care for adults with metastatic spinal cord compression

This quality statement is taken from the metastatic spinal cord compression in adults quality standard. The quality standard defines clinical best practice in metastatic spinal cord compression care for adults and should be read in full.

Quality statement

Adults with metastatic spinal cord compression (MSCC) have their ongoing care coordinated by an MSCC coordinator.

Rationale

The care and treatment of adults with MSCC may involve a number of specialties including oncology, surgery and radiology. It is important that the ongoing investigations and treatments are undertaken promptly because early intervention has a positive effect on MSCC outcomes. The principal role of the MSCC coordinator for adults with MSCC is to liaise with the relevant specialists and organise treatment and any ongoing investigations, ensuring that the ongoing care of adults with MSCC is both comprehensive and timely.

Quality measures

Structure
a) Evidence of local arrangements for identifying individuals responsible for performing the role of MSCC coordinator.
b) Evidence of local arrangements to ensure that adults with MSCC have their ongoing care coordinated by an MSCC coordinator.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-3Y-304 (The MSCC Coordinator Service) Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011).

What the quality statement means for service providers, healthcare professionals, and commissioners

Service providers ensure that an MSCC coordinator is available to coordinate the ongoing care for adults with MSCC.
Healthcare professionals ensure that they arrange access to the MSCC coordinator who will coordinate the ongoing care for adults with MSCC.
Commissioners ensure that they commission services that provide access to an MSCC coordinator who will coordinate the ongoing care for adults with MSCC.

What the quality statement means for patients, service users and carers

Adults with MSCC have their treatment organised by a coordinator who will oversee important aspects of care on their behalf.

Source guidance

Definitions of terms used in this quality statement

MSCC coordinator role
The role involves coordinating the ongoing care of adults with MSCC and the diagnostic investigations of people at risk of developing MSCC who present with relevant symptoms. An MSCC coordinator should be available 24 hours a day, 7 days a week, acting as a single point of contact for healthcare professionals to liaise with.
The MSCC coordinator’s responsibilities and the support they should receive are described in NICE clinical guideline 75 recommendations 1.1.2.3 and 1.1.2.5.
The Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011; measure 11-3Y-304) lists the criteria that the MSCC coordinator service should fulfil.

Treatment of metastatic spinal cord compression

This quality statement is taken from the metastatic spinal cord compression in adults quality standard. The quality standard defines clinical best practice in metastatic spinal cord compression care for adults and should be read in full.

Quality statement

Adults with metastatic spinal cord compression (MSCC), who present with neurological symptoms or signs, start definitive treatment (if appropriate) within 24 hours of the confirmed diagnosis.

Rationale

Treatment while patients are still able to move or walk around is effective in maintaining their ability to walk and functional independence. Delay in treatment may have irreversible consequences, such as loss of motor and bladder functions. Starting definitive treatment as a matter of urgency is important for adults with MSCC because it can help to prevent further neurological deterioration, which may lead to paraplegia. People who develop paraplegia have a significantly impaired quality of life and shortened survival, and so it is important to identify possible ways of preventing or improving the outcome of MSCC.

Quality measures

Structure
Evidence of local arrangements and written protocols to ensure that adults with MSCC who present with neurological symptoms or signs start definitive treatment (if appropriate) within 24 hours of the confirmed diagnosis.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-1E-112y (The Audit of Timeliness of Definitive Treatment of MSCC) Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011).
Process
Proportion of adults with MSCC who present with neurological symptoms or signs who start definitive treatment (if appropriate) within 24 hours of the confirmed diagnosis.
Numerator – the number of adults in the denominator who start definitive treatment within 24 hours of the confirmed diagnosis.
Denominator – the number of adults with MSCC who present with neurological symptoms or signs for whom it is appropriate to start definitive treatment within 24 hours.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-1E-112y (The Audit of Timeliness of Definitive Treatment of MSCC) Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011).
Outcome
a) Proportion of adults with MSCC who are able to walk within 3 months of treatment.
b) Proportion of adults with MSCC who are able to walk within 2 years of treatment.
c) Rates of mortality within 30 days of treatment.
Data source: Local data collection. Department of Health Acute Oncology Measures 11-1E-113y Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011). British Spine Registry Spinal tumour data (2013).

What the quality statement means for service providers, healthcare professionals, and commissioners

Service providers ensure that for adults with MSCC presenting with neurological symptoms or signs adequate capacity is available and that there are local protocols in place to enable healthcare professionals to start definitive treatment (if appropriate) within 24 hours of the confirmed diagnosis.
Healthcare professionals ensure that for adults with MSCC who present with neurological symptoms or signs they start definitive treatment (if appropriate) within 24 hours of the diagnosis being confirmed.
Commissioners ensure that for adults with MSCC who present with neurological symptoms or signs they commission services that can start definitive treatment (if appropriate) within 24 hours of the confirmed diagnosis.

What the quality statement means for patients, service users and carers

Adults with MSCC for whom treatment is appropriate start their treatment as quickly as possible (ideally within 24 hours of being diagnosed with MSCC).

Source guidance

Definitions of terms used in this quality statement

Definitive treatment
Definitive treatment for MSCC includes surgery and radiotherapy. [Department of Health Acute Oncology Measures (The Audit of Timeliness of Definitive Treatment of MSCC) Manual for cancer services: acute oncology – including metatastic spinal cord compression measures (2011)]
Symptoms and signs of MSCC
The following symptoms and signs are suggestive of MSCC:
  • progressive pain in the spine
  • severe unremitting spinal pain
  • spinal pain aggravated by straining (for example, at stool, when coughing or sneezing, or when moving)
  • pain described as ‘band like’
  • localised spinal tenderness
  • nocturnal spinal pain preventing sleep
  • neurological symptoms: radicular pain, any limb weakness, difficulty in walking, sensory loss, or bladder or bowel dysfunction.
  • neurological signs of spinal cord or cauda equina compression.
[Definition developed from NICE clinical guideline 75 recommendations 1.3.2.1 and 1.3.2.2 and expert consensus]

Equality and diversity considerations

Survival times for adults with MSCC vary from just a few weeks to over a decade. The person’s age should not affect the decision to undertake definitive treatment.

Supportive care and rehabilitation

This quality statement is taken from the metastatic spinal cord compression in adults quality standard. The quality standard defines clinical best practice in metastatic spinal cord compression care for adults and should be read in full.

Quality statement

Adults with metastatic spinal cord compression (MSCC) have a management plan that includes an assessment of ongoing care and rehabilitation needs.

Rationale

It is important that personalised management planning for adults with MSCC starts on admission because rehabilitation and supportive care are integral to the promotion of independence and quality of life for adults with MSCC. Emphasis should be on an individualised, person-centred management planning process, led by a key worker, which takes into account care relating to all existing healthcare issues the person may have, including cancer. Communication between secondary, primary and tertiary care needs to ensure a seamless transfer between services and continuity of care for patients.

Quality measures

Structure
Evidence of local arrangements and written protocols to ensure that management planning for adults with MSCC includes an assessment of ongoing care and rehabilitation needs.
Data source: Local data collection.
Process
Proportion of adults with MSCC who are discharged from hospital with a management plan that includes an assessment of ongoing care and rehabilitation needs.
Numerator – the number of adults in the denominator who have a management plan on discharge.
Denominator – the number of adults with MSCC who are admitted to hospital.
Data source: Local data collection.

What the quality statement means for service providers, healthcare professionals and commissioners

Service providers ensure that staff are trained on how to develop management plans, including how to undertake an assessment of ongoing care and rehabilitation needs for adults with MSCC, and have protocols in place for starting management planning on admission.
Healthcare professionals involve adults with MSCC in developing management plans that include an assessment of ongoing care and rehabilitation needs for adults with MSCC when they are admitted to hospital.
Commissioners ensure that they commission services that train their staff on how to develop management plans including how to undertake an assessment of ongoing care and rehabilitation needs for adults with MSCC, and have protocols in place for starting management planning on admission.

What the quality statement means for patients, service users and carers

Adults with MSCC have a plan of the ongoing care they agree they will receive after they have been discharged from hospital, which will include plans for rehabilitation.

Source guidance

  • Metastatic spinal cord compression (NICE clinical guideline 75), recommendation 1.6.5.4 (key priority for implementation).

Definitions of terms used in this quality statement

Management planning and ongoing care
For adults with MSCC, this should start on admission and it should involve: the patient; their families and carers with the patient’s consent; their primary oncology site; surgical, specialist palliative care and rehabilitation teams and community support, including primary care, as needed. The management plan should address physical and psychological needs. Management planning should include, but not be limited to, consideration of: pressure ulcers, continence, maintenance of circulatory and respiratory functioning, psychological adjustment and location of care. [NICE clinical guideline 75 recommendation 1.6.5.4 and expert consensus]
Key worker
Person who, with the patient’s consent and agreement, takes the leading role in coordinating the patient’s care and promoting continuity, ensuring the patient knows who to access for information and advice, regardless of the patient’s location. The role may be undertaken by the MSCC coordinator or by a different named individual. Different practitioners are likely to perform this function on behalf of individual patients over time. [Adapted from the full clinical guideline 75, appendix 6, glossary; NICE cancer service guidance on Supportive and palliative care, recommendation 1.29 and expert consensus]

Equality and diversity considerations

Survival times for adults with MSCC vary from just a few weeks to over a decade. MSCC is closely associated with the end of life because of its high incidence in the late stages of advanced malignancy. The timing of discussions about ongoing care and rehabilitation should be sensitive to the emotional adjustments that the patient and carer may be experiencing.
The person’s age should not affect the content of the discharge plan or their access to rehabilitation services. Healthcare professionals should consider whether adults with MSCC who are experiencing the later stages of cancer may benefit more from readjustment rather than rehabilitation.

Effective interventions library

Effective interventions library

Successful effective interventions library details

Implementation

Information for the public

NICE has written information for the public on each of the following topics.

Pathway information

Person-centred care

People have the right to be involved in discussions and make informed decisions about their care, as described in your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

Your responsibility

Guidelines

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Technology appraisals

The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take these recommendations fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this interactive flowchart is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the recommendations to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Medical technologies guidance, diagnostics guidance and interventional procedures guidance

The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take these recommendations fully into account. However, the interactive flowchart does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the recommendations, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this interactive flowchart should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Supporting information

Glossary

American Society of Anaesthetists
metastatic spinal cord compression
spinal pain that is not progressive, severe or aggravated by straining and has no accompanying neurological symptoms
short T1 inversion recovery

Paths in this pathway

Pathway created: January 2012 Last updated: October 2017

© NICE 2017. All rights reserved. Subject to Notice of rights.

Recently viewed